Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced BCC and metastatic BCC~* Patients with adequate bone marrow, liver, and renal function~Exclusion Criteria:~* Patients who had had major surgery within 4 weeks of initiation of study medication~* Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes.~* Patients with concurrent medical conditions that may interfere or potentially affect the interpretation of the study.~* Patients with neuromuscular disorders or are on concurrent treatment with drugs that may cause muscle damage.~* Patients who were on concurrent therapy with other anti-neoplastic agents.~* Patients who had taken part in an experimental drug within 4 weeks of initiation of study medication.~* Pregnant or nursing (lactating) women~* Women of child bearing potential unwilling to use 2 forms of highly effective contraception throughout the study and for 3 months after the last treatment~* Fertile males not willing to use condoms throughout the study and for 3 months after the last treatment.~* Patients who were unwilling or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDE225 200 mg (Type: EXPERIMENTAL): The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
- LDE225 800 mg (Type: EXPERIMENTAL): The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).